Trials / Completed
CompletedNCT02116582
A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 215 (actual)
- Sponsor
- Astellas Pharma Europe B.V. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to evaluate the efficacy and safety of enzalutamide treatment in patients with progressive metastatic castration-resistant prostate cancer previously treated with abiraterone acetate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzalutamide | Participants received 160 mg of enzalutamide (soft capsules) orally once daily. |
Timeline
- Start date
- 2014-05-23
- Primary completion
- 2016-05-08
- Completion
- 2017-09-29
- First posted
- 2014-04-17
- Last updated
- 2024-12-06
- Results posted
- 2017-06-08
Locations
50 sites across 5 countries: Belgium, France, Germany, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02116582. Inclusion in this directory is not an endorsement.